RayKnowChina Research Map
Shortlist

Cancer

Lung cancer in Qingdao

青岛 肺癌

All diseases in Qingdao

2 hospitals in Qingdao

Order: papers led on lung cancer, 2021–2025, then A–Z. Research activity, not a rating of care.

Only hospitals listed for lung cancer: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Qingdao may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.

  1. 123 papers led
  2. 2 papers led

Lung cancer in every city Qingdao on the disease page, with the national map

19

open trials on lung cancer with a hospital in Qingdao

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Qingdao as lead sponsor or study site. 3 of them are led by a hospital in Qingdao. Check the registry for the current status. Whether someone can take part is decided by the study team.

Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.

  1. Recruiting
    A Study of DXC014 in Patients With Advanced Solid Tumors.
    Phase
    Phase 1
    Started
    2026-03
    Posted
    Registry
    NCT07177937

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Nanchang, Qingdao

  2. Recruiting
    RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
    Phase
    Phase 3
    Started
    2026-04
    Posted
    Registry
    NCT07416474

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 66 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Urumqi, Wenzhou, Wuhan, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yantai, Yinchuan, Zhengzhou, Zhuhai

  3. Recruiting
    Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC
    Phase
    Not given
    Started
    2026-03
    Posted
    Registry
    NCT07528066

    Age not stated (registered criteria)

    Led by Shanghai Chest Hospital; 6 listed hospitals as study sitesFuzhou, Guangzhou, Nanjing, Qingdao, Shanghai, Shenzhen, Tianjin

  4. Recruiting
    RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC
    Phase
    Not given
    Started
    2026-04
    Posted
    Registry
    NCT07541521

    Age not stated (registered criteria)

    Led by Shanghai Chest Hospital; 6 listed hospitals as study sitesFuzhou, Guangzhou, Nanjing, Qingdao, Shanghai, Shenzhen, Tianjin

  5. Recruiting
    Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
    Phase
    Not given
    Started
    2025-02
    Posted
    Registry
    NCT06809764

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 30 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Wuhan, Xiamen, Zhengzhou

  6. Recruiting
    A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07111520

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan, Xiangyang, Xinxiang, Xuzhou, Yangzhou

  7. Recruiting
    A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
    Phase
    Not given
    Started
    2025-12
    Posted
    Registry
    NCT07143045

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesChangchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Harbin, Hefei, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shenyang, Shenzhen, Taiyuan, Tianjin, Wuhan, Xiamen, Yangzhou, Zhengzhou

  8. Recruiting
    Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07185997

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xinxiang, Zhengzhou

  9. Recruiting
    Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT07322783

    Age 18 years to 80 years (registered criteria)

    Led by Qingdao Central HospitalQingdao

  10. Recruiting
    JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
    Phase
    Phase 3
    Started
    2024-08
    Posted
    Registry
    NCT06416410

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Wuxi, Xi'an, Zhengzhou

  11. Recruiting
    Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer
    Phase
    Not given
    Started
    2024-04
    Posted
    Registry
    NCT06514118

    Age 18 years to 80 years (registered criteria)

    Led by Qingdao Central HospitalQingdao

  12. Recruiting
    Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT06095583

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Yinchuan, Zhengzhou

  13. Recruiting
    Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC
    Phase
    Phase 2
    Started
    2022-09
    Posted
    Registry
    NCT05536505

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou, Hefei, Qingdao, Shanghai, Shenzhen, Wuhan, Xiamen, Zhongshan

  14. Recruiting
    Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Posted
    Registry
    NCT04930432

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 56 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

  15. Not yet recruiting
    A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer
    Phase
    Phase 4
    Started
    2026-05
    Posted
    Registry
    NCT07485920

    Age 18 years to Not stated (registered criteria)

    Led by Affiliated Hospital of Qingdao University; 1 listed hospital as study siteQingdao, Yantai

  16. Not yet recruiting
    A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver Function
    Phase
    Phase 1
    Started
    2026-04
    Posted
    Registry
    NCT07538973

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesQingdao, Shanghai

  17. Not yet recruiting
    A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Phase
    Phase 2/Phase 3
    Started
    2026-11
    Posted
    Registry
    NCT07865910

    Age 18 days to 75 days (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesAnyang, Beijing, Chongqing, Guangzhou, Jinan, Nanning, Qingdao, Shijiazhuang, Wuhan, Xuzhou, Zhengzhou, Zunyi

  18. Not yet recruiting
    YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
    Phase
    Phase 3
    Started
    2023-05
    Posted
    Registry
    NCT05767892

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou

  19. Not yet recruiting
    A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT05990127

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luoyang, Nanchang, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Disease research in Qingdao

Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.

A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.

Papers led and open trials led by hospitals in Qingdao, by disease
CancerBlood disordersOther diseases
HospitalNasopharyngeal carcinomaOesophageal squamous cell carcinomaHepatocellular carcinomaStomach cancerLung cancerPancreatic cancerBreast cancerGliomaHepatoblastomaRetinoblastomaChordomaOsteosarcomaGastrointestinal stromal tumourNeuroblastomaEwing sarcomaMultiple myelomaB-cell acute lymphoblastic leukaemiaAplastic anaemiaHaemophagocytic lymphohistiocytosisLymphomaBeta thalassaemiaHaemophilia AAtypical haemolytic uraemic syndromeThrombotic thrombocytopenic purpuraFanconi anaemiaNeuromyelitis optica spectrum disorderIgG4-related diseaseMyasthenia gravisMoyamoya diseaseWilson diseaseBiliary atresiaCoronary heart diseaseCongenital heart diseaseScoliosisAnti-NMDA receptor encephalitisTakayasu arteritisHepatic echinococcosisIdiopathic pulmonary fibrosisLymphangioleiomyomatosisAmyotrophic lateral sclerosisSpinal muscular atrophyFabry diseasePompe diseaseDuchenne muscular dystrophyBehçet diseaseAlport syndromeIgA nephropathyGaucher diseaseNiemann–Pick disease type COsteogenesis imperfectaPrimary biliary cholangitisPrimary sclerosing cholangitisCongenital diaphragmatic herniaHirschsprung diseaseInherited epidermolysis bullosaHereditary angioedemaFamilial adenomatous polyposisLeber hereditary optic neuropathyMajeed syndromeNGLY1 deficiencyISG15 deficiencyShortlist
Affiliated Hospital of Qingdao University青岛大学附属医院38701057 open1231 open47803 open3162116792807225none000none11 open221 open22none181 open93none0none3none2nonenone11nonenone111none62nonenone1none11nonenonenone
Affiliated Taian Central Hospital of Qingdao University泰安市中心医院nonenonenonenonenonenonenonenonenonenonenonenone11nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Children's Hospital, Qingdao University青岛大学附属妇女儿童医院nonenonenonenonenonenonenonenonenonenonenonenonenone3nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone10nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Qilu Hospital of Shandong University, Qingdao山东大学齐鲁医院(青岛)nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenone
Qingdao Central Hospital康复大学青岛中心医院none02none22 open02nonenone0none0nonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenone01 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Qingdao Central Hospital, University of Health青岛市中心医院nonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenone0nonenonenone
Qingdao Chengyang People's Hospital青岛市城阳区人民医院nonenonenonenonenonenonenonenonenonenonenone0none10nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Qingdao Eighth People's Hospital青岛市第八人民医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Qingdao Hospital青岛市海慈医疗集团nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenone
Qingdao Municipal Hospital青岛市市立医院nonenone175none8nonenonenone1nonenonenone0none2nonenonenonenone0nonenonenonenonenonenonenonenonenonenone5nonenonenonenonenonenonenone3none0nonenone111nonenonenonenonenonenonenonenonenone1nonenonenonenone
Qingdao Third People's Hospital青岛市第三人民医院nonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Qingdao West Coast New Area Central Hospital青岛西海岸新区中心医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Qingdao West Coast New District People's Hospital青岛西海岸新区人民医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Qingdao Women and Children's Hospital青岛市妇女儿童医院nonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenone0nonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Songshan Hospital, Qingdao University Medical College青岛大学医学院松山医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone

Column labels are short names. Choose one to open that disease in Qingdao.

Other cities nearby

Straight-line distance from the city centre; counts are hospitals listed for lung cancer.

Counts are listed hospitals only, not every hospital in each city.

Where these numbers come from

Papers

English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions

Trials

ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Qingdao on ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data